ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET FORECAST 2023-2032

The Asia-Pacific head & neck cancer therapeutics market growth evaluation entails the study of China, Japan, India, South Korea, Indonesia, Vietnam, Thailand, Australia & New Zealand, and Rest of Asia-Pacific. China, known as the world’s largest producer and consumer of tobacco, faces significant challenges in tobacco control. With over 300 million smokers, accounting for approximately one-third of the global smoking population, and more than half of adult men currently smoking cigarettes, the country grapples with widespread tobacco use. Besides, approximately 700 million non-smokers, including 180 million children, are exposed to second-hand smoke on a weekly basis, resulting in the deaths of 100,000 people annually. Head and neck cancers are among the most prevalent cancers in China, with an estimated 117,000 new cases projected in 2020, as reported by the International Agency for Research on Cancer (IARC). Alcohol and tobacco use are identified as significant risk factors for head and neck cancer, and their combined use further escalates the risk.

In addition, while betel nut chewing is not as widespread in Japan as in some other Asian nations, it remains a cultural tradition in certain regions. When consumed in conjunction with other substances, betel nuts can increase the likelihood of developing oral and other head and neck cancers. Dietary factors may also contribute to the higher incidence of head and neck cancers in Japan. Moreover, despite being generally regarded as healthy, the traditional Japanese diet includes various pickled vegetables and salt-preserved items that have been associated with an elevated risk of certain cancers, particularly those affecting the head and neck. Hence, such factors are projected to augment the head & neck cancer therapeutics market growth in the Asia-Pacific during the forecast years.

The Asia-Pacific head & neck cancer therapeutics market is segmented into therapeutic class, treatment type, route of administration, and end-user. The route of administration segment includes injectable and oral. Injectable medications can be utilized in combination with treatment techniques such as surgery, radiation therapy, or systemic medicines like chemotherapy or immunotherapy. 

The synergy achieved by combining different therapy modalities improves treatment outcomes. Injectable pharmaceuticals provide an additional therapeutic option that can be integrated into comprehensive treatment plans. By enabling targeted delivery of therapeutic drugs through intravenous or systemic administration at the tumor site, injectable therapies focus the treatment on cancer cells while minimizing damage to healthy tissues and organs. 

Some of the main players operating in the Asia-Pacific head & neck cancer therapeutics market include Sun Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Pfizer, etc.

Pfizer Inc develops, manufactures, and sells biopharmaceuticals and is headquartered in the United States. The company distributes medications that help treat a diverse range of conditions, including cancer, rare diseases, inflammation, cardiovascular, and other ailments. Moreover, the company also provides biosimilars, active pharmaceutical ingredients (APIs), sterile injectable drugs, as well as contract manufacturing services.